Hashish inhaler co Syqe Medical lays off 50

Israeli hashish inhaler firm Syqe Medical has confirmed that it’s shedding 50 staff representing one third of its workforce. Syqe has developed inhaling applied sciences to manage measured and constant doses of medical hashish. The corporate was based in 2011 by Perry Davidson and is managed by CEO Hagit Kamin.

Davidson based the corporate to unravel one of many main issues with hashish – the shortage of uniformity between totally different doses. Even when the hashish itself might be replicated, which means that the crops are all the time the identical and processed in the identical approach, a deeper inhalation can change the way in which the substance impacts sufferers, introducing a component of unpredictability, which may hurt the standard of therapy. Syqe’s inhaler was developed to permit for a exact and measured dose, and within the course of has been in a position to obtain effectiveness even with small doses.

Syqe begins advertising medical hashish inhaler

In 2019-2021, there was nice enthusiasm available in the market about the potential of administering hashish in a way just like prescribed drugs, and Syqe’s expertise was one of the promising within the subject. Right this moment, the corporate nonetheless reviews income, however the emphasis on measured and exact inhalation is barely a really particular area of interest available in the market.

The corporate presently stresses not solely dose measurements, but additionally the potential of utilizing its product to attain outcomes with a comparatively low dosage, whereas minimizing unintended effects.

Cooperation in Israel and Australia

A number of months in the past, the corporate introduced a collaboration with the Australian Division of Veterans’ Affairs (DVA), during which the division totally backed Syqe’s inhaler. The approval follows Syqe’s collaboration with Israel’s Ministry of Protection, during which the inhaler has been supplied to hundreds of sufferers, disabled throughout army service, and affected by power ache and post-traumatic stress dysfunction (PTSD). Syqe had a earlier settlement in Australia, during which its inhaler is supplied to victims of labor accidents.

It was beforehand reported that Syqe was to be bought to tobacco firm Philip Morris, which is one in all its buyers together with Retallix founders Barry Shaked and Brian Cooper, OurCrowd, Shavit Capital, the Martin Bauer Group’s PRM funding arm and others. Philip Morris does have an choice to steadily purchase Syqe primarily based on milestones.

Syqe stated, “Syqe is adjusting the corporate’s construction throughout the second part of the scientific trial and is accordingly making changes to the workforce construction, primarily within the improvement division. Specializing in the scientific course of is a major a part of realizing the corporate’s targets, together with FDA approval, and accordingly, the corporate will deepen its sources on this space. As well as, Saiki will proceed to develop its actions in backed markets, together with Israel.”

Printed by Globes, Israel enterprise information – en.globes.co.il – on July 17, 2025.